Product Description
The study medication, elimusertib, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04095273)
Mechanisms of Action: ATR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Germany, Japan, Singapore, Spain, Switzerland, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 4
Highest Development Phases
Phase 1: Ataxia Telangiectasia|Lymphoma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20182524 | P1 |
Completed |
Lymphoma |
2023-09-13 |
|
| JapicCTI-183998 | P1 |
Active |
Lymphoma|Ataxia Telangiectasia |
2023-02-15 |
|
| NCT03188965 | P1 |
Completed |
Mantle-Cell Lymphoma|Lymphoma, Non-Hodgkin |
2022-12-02 |
28% |
| KEYNOTE-919 | P1 |
Completed |
Ataxia Telangiectasia |
2022-11-24 |
28% |